Physicians' Academy for Cardiovascular Education

CV Protection in the EMPA-REG OUTCOME Trial: A ‘Thrifty Substrate’ Hypothesis

Lecture - July 31, 2016 - Asian Interchange on Diabetes meeting - Michael Mark, MD, Boehringer Ingelheim – Cardiometabolic Diseases Research

Michael Mark proposes a new hypothesis that may explain the observed CV benefit of empagliflozin, involving increased haematocrit and higher ketone bodies as a potent alternative energy source.

This lecture was recorded at the Asian Interchange on Diabetes meeting, held in Bangkok on July 30-31, 2016.

Video navigation menu

  • A recap of the study design of the EMPA-REG OUTCOME study 0:41
  • A closer look at the mortality benefit seen with empagliflozin treatment as compared with placebo 2:07
  • Speculating on the underlying mechanism of the CV benefit seen with empagliflozin treatment 4:15
  • A new hypothesis emerges: empagliflozin increases oxygen delivery to organs by increasing hematocrit 11:03
  • Part two of the new hypothesis, involving increased ketone bodies featuring as a 'superfuel' 16:08
  • A covariate analysis of the EMPA-REG OUTCOME data provides evidence for the new hypothesis 23:13

The content is aimed for medical professionals. To view this item member registration is needed. Register for free to get unlimited access to our educational resources.
The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: